Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

It’s been a month since cancer drug developers presented their latest research at the American Society of Clinical Oncology (ASCO) annual meeting, and the highlights are still reverberating across the industry.

Updates on Bayer’s Vitrakvi (larotrectinib) were presented across several sessions, including one regarding the efficacy and safety of the oral medicine in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer.